+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, engaged in the discovery and commercialization of molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company’s product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions, and corresponding proteins to assess a person’s risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient’s likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Canada, Middle East, Asia, and Australia. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia, and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc Key Recent Developments

  • Dec 19, 2022: Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
  • Nov 14, 2022: Myriad Genetics Focuses on expanding access, collaboration and equity in genetic testing at national society of genetic counselors meeting
  • Nov 01, 2022: Myriad Genetics Reports Third Quarter Financial Results
  • Oct 31, 2022: Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Myriad Genetics Inc - Key Facts
  • Myriad Genetics Inc - Key Employees
  • Myriad Genetics Inc - Key Employee Biographies
  • Myriad Genetics Inc - Major Products and Services
  • Myriad Genetics Inc - History
  • Myriad Genetics Inc - Company Statement
  • Myriad Genetics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Myriad Genetics Inc - Business Description
  • Product Category: Autoimmune
  • Performance
  • Product Category: Hereditary Cancer
  • Overview
  • Performance
  • Product Category: Pharmacogenomics
  • Overview
  • Performance
  • Product Category: Prenatal
  • Overview
  • Performance
  • Product Category: Tumor Profiling
  • Overview
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Myriad Genetics Inc - Corporate Strategy
  • Myriad Genetics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Myriad Genetics Inc - Strengths
  • Myriad Genetics Inc - Weaknesses
  • Myriad Genetics Inc - Opportunities
  • Myriad Genetics Inc - Threats
  • Myriad Genetics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Myriad Genetics Inc, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Myriad Genetics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Dec 19, 2022: Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
  • Nov 14, 2022: Myriad Genetics Focuses on expanding access, collaboration and equity in genetic testing at national society of genetic counselors meeting
  • Nov 01, 2022: Myriad Genetics Reports Third Quarter Financial Results
  • Oct 31, 2022: Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
  • Aug 04, 2022: Myriad Genetics Reports Second Quarter Financial Results
  • Jul 19, 2022: Myriad Genetics to share update on business transformation, research and development pipeline, and growth plans at investor day on Aug. 11, 2022
  • Jun 23, 2022: Myriad Genetics teams up with Epic to make genetic testing accessible to more patients with Electronic Health Record (EHR) Integration
  • Jun 09, 2022: Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference
  • May 17, 2022: Shadowbox technology facilitated orders of Myriad Genetics germline diagnostic, increasing volume by more than 800%
  • May 04, 2022: Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Myriad Genetics Inc, Key Facts
  • Myriad Genetics Inc, Key Employees
  • Myriad Genetics Inc, Key Employee Biographies
  • Myriad Genetics Inc, Major Products and Services
  • Myriad Genetics Inc, History
  • Myriad Genetics Inc, Subsidiaries
  • Myriad Genetics Inc, Key Competitors
  • Myriad Genetics Inc, Ratios based on current share price
  • Myriad Genetics Inc, Annual Ratios
  • Myriad Genetics Inc, Interim Ratios
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Myriad Genetics Inc, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Myriad Genetics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Myriad Genetics Inc, Performance Chart (2018 - 2022)
  • Myriad Genetics Inc, Ratio Charts
  • Myriad Genetics Inc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Myriad Genetics Inc, Medical Equipment, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Hologic Inc
  • Laboratory Corporation of America
  • InVitae Corp
  • Ambry Genetics Corp
  • Quest Diagnostics Inc
  • Exact Sciences Corp
  • Natera Inc
  • Genomind Inc
  • DNA Diagnostics Center Inc
  • Foundation Medicine Inc